Clinical Trials Logo

Filter by:
NCT ID: NCT02328820 Completed - Clinical trials for Coronary Artery Disease

Combined Pressure and Flow Measurements to Guide Treatment of Coronary Stenoses

DEFINE-FLOW
Start date: October 2014
Phase: N/A
Study type: Interventional

This study evaluates the prognostic value and therapeutic potential of combined pressure and flow measurements when evaluating a coronary artery stenosis. Lesions with intact coronary flow reserve (CFR) despite a reduced fractional flow reserve (FFR) will receive optimal medical therapy. Only lesions with a simultaneous reduction in both CFR and FFR will be treated with percutaneous coronary intervention (PCI).

NCT ID: NCT02328417 Completed - Bladder Cancer Clinical Trials

Enhanced Recovery After Radical Cystectomy Study

Start date: December 2014
Phase: N/A
Study type: Observational

Prospective non randomized study of two cohorts: usual protocol and the application of accelerated recovery protocol. F/up after discharge, 90 days and thereafter according to protocol of each center. Compliance to be assessed.

NCT ID: NCT02328066 Completed - Colonic Polyps Clinical Trials

Diagnostic Accuracy of NICE Classification to Predict Deep Submucosal Invasion

NICE
Start date: July 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the diagnostic accuracy of NICE classification to predict deep submucosal invasion of colonic polyps > 1 cm, considering histology as the gold standard, in a group of endoscopists who previously performed a training program.

NCT ID: NCT02327975 Completed - Aged Clinical Trials

Prescription of Physical Exercise Through Mobile Application in Elderly

PEME
Start date: November 2012
Phase: N/A
Study type: Interventional

Physical inactivity is a health problem that affects people worldwide and has been identified as the fourth largest risk factor for overall mortality (contributing to 6% of deaths globally). Many researchers have tried to increase physical activity (PA) levels through traditional methods without much success. Thus, many researchers are turning to mobile technology as an emerging method for changing health behaviours.The study consists of a physical activity intervention through a mobile application in elderly. The study is a 3x2 model, in which the sample is distributed in three study groups (over 53 years) and were evaluated at 10 weeks from baseline.

NCT ID: NCT02327169 Completed - Clinical trials for Advanced Nonhematologic Malignancies

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

Start date: January 14, 2015
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to determine the safety profile and the maximum tolerated doses (MTDs)/ potential recommended phase 2 doses (RP2Ds) of the combination treatments of MLN2480 + MLN0128, MLN2480 + alisertib, MLN2480 + paclitaxel, MLN2480 + cetuximab, and MLN2480 + irinotecan in participants with advanced nonhematologic malignancies.

NCT ID: NCT02325791 Completed - Clinical trials for Respiratory Syncytial Virus Infections

Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

Start date: July 21, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the efficacy, safety, pharmacokinetics (PK), and immunogenicity of suptavumab (REGN2222) in infants born no more than 35 weeks, 6 days gestational age who are no more than 6 months of age at the time of enrollment in their respective geographic location. In order to optimize the potential benefit in this vulnerable population, we conducted this study during the RSV season using dosing regimens that are expected to be effective.

NCT ID: NCT02325739 Completed - Clinical trials for Hepatocellular Carcinoma (HCC)

FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression

Start date: December 29, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Estimate the maximum tolerated dose and/or recommended phase II dose and efficacy of FGF401 as single agent and in combination with PDR001 in patients with hepatocellular carcinoma and as single agent in patients with other solid malignancies based on RECIST 1.1.

NCT ID: NCT02325258 Completed - Sepsis Clinical Trials

Assessment of a Proposed Microbiological Alert and Its Impact on a Sepsis Campaign

Start date: August 2012
Phase: N/A
Study type: Interventional

The aim of the present study was to evaluate the ability of health-care professionals in addressing sepsis, and the impact of a telephone call upon receival of blood cultures in the clinical microbiology department, from a clinical microbiologist, in the early management of sepsis.

NCT ID: NCT02324920 Completed - Syncope Clinical Trials

Benefit of Dual-chamber Pacing With Closed Loop Stimulation (CLS) in Tilt-induced Cardioinhibitory Reflex Syncope

BIOSync CLS
Start date: October 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to assess whether the Closed Loop Stimulation (CLS) in addition to the DDD pacing is effective in reducing syncopal recurrences. The study hypothesis is that DDD pacing with CLS stimulation is able to prevent syncopal recurrences completely or partially by transforming syncope in pre-syncope.

NCT ID: NCT02324855 Completed - Bronchiectasis Clinical Trials

Long-term Airway Clearance Therapy in Non-cystic Fibrosis Bronchiectasis

Start date: October 2015
Phase: N/A
Study type: Interventional

The main aim is to analyze whether the routine use of chest physiotherapy in non cystic fibrosis bronchiectasis (NCFB) improves the cough severity and the quality of life in this population. In addition, the secondary end-points include incidences of exacerbations, changes in lung function, exercise capacity, airways inflammation, sputum analysis and eventual adverse events.